Updated on 14 October 2015
WuXi has launched an app to record oncology data
Singapore: WuXi PharmaTech, biotech outsourcing company, has launched a mobile version of OncoWuXi, an app to allow researchers to access oncology models and data on the go. The OncoWuXi App helps WuXi's clients anywhere and at any time to identify relevant tumor models for use in anti-tumor efficacy testing to facilitate oncology drug discovery and translational oncology, as well as to keep up-to-date on WuXi's capabilities and services in this area.
The OncoWuXi App provides users with a portable oncology database for selection and inquiry of the more than 1,000 cancer patient-derived xenograft (PDX), human cancer cell-derived xenograft (CDX), and syngeneic mouse tumor models available at WuXi. Its backend database covers every aspect of those models, including growth dynamics, histopathology, clinical information, genomic profiles, and Standard of Care (SoC) validation data. Users may also submit service requests regarding particular models from the App directly to WuXi Oncology.
The App can be used on either Apple or Android devices.
"WuXi has long been committed to bringing our customers the most advanced products and services for discovering and developing innovative drugs," said Dr Ge Li, chairman and CEO, WuXi PharmaTech. "Beginning with WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis, which we launched earlier this year, and now with OncoWuXi, we are striving to enable our customers to access our platform capabilities and technologies more quickly and easily."